Page last updated: 2024-08-17

biguanides and tak-875

biguanides has been researched along with tak-875 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Enya, K; Kaku, K; Matsuno, R; Nakaya, R; Ohira, T	1

Trials

1 trial(s) available for biguanides and tak-875

Article	Year
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:9 Topics: Benzofurans; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Japan; Liver; Male; Middle Aged; Receptors, G-Protein-Coupled; Sulfones; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2016

Article

Year

Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.

Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:9

Topics: Benzofurans; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Japan; Liver; Male; Middle Aged; Receptors, G-Protein-Coupled; Sulfones; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2016